US6210708B1 - Cationic virosomes as transfer system for genetic material - Google Patents

Cationic virosomes as transfer system for genetic material Download PDF

Info

Publication number
US6210708B1
US6210708B1 US09/414,872 US41487299A US6210708B1 US 6210708 B1 US6210708 B1 US 6210708B1 US 41487299 A US41487299 A US 41487299A US 6210708 B1 US6210708 B1 US 6210708B1
Authority
US
United States
Prior art keywords
virosomes
vesicle
cell
lipids
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/414,872
Other languages
English (en)
Inventor
Ernst Rudolf Walti
Reinhard Gluck
Peter Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nika Health Products Ltd
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Assigned to NIKA HEALTH PRODUCTS LIMITED reassignment NIKA HEALTH PRODUCTS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GLUCK, REINHARD, KLEIN, PETER, WALTI, ERNST RUDOLF
Priority to JP2001529418A priority Critical patent/JP2003512306A/ja
Priority to PCT/EP2000/009540 priority patent/WO2001026628A1/en
Priority to DK00967824T priority patent/DK1217990T3/da
Priority to EP00967824A priority patent/EP1217990B1/en
Priority to KR1020027004325A priority patent/KR100869195B1/ko
Priority to PL00355231A priority patent/PL355231A1/xx
Priority to CA002388053A priority patent/CA2388053A1/en
Priority to TR2002/00930T priority patent/TR200200930T2/xx
Priority to SK478-2002A priority patent/SK4782002A3/sk
Priority to AU77850/00A priority patent/AU778399B2/en
Priority to CZ20021216A priority patent/CZ20021216A3/cs
Priority to HU0202809A priority patent/HUP0202809A2/hu
Priority to DE60008006T priority patent/DE60008006T2/de
Priority to AT00967824T priority patent/ATE258428T1/de
Priority to RU2002112224/15A priority patent/RU2002112224A/ru
Priority to ES00967824T priority patent/ES2215073T3/es
Priority to CO00076243A priority patent/CO5280052A1/es
Priority to PE2000001071A priority patent/PE20010703A1/es
Publication of US6210708B1 publication Critical patent/US6210708B1/en
Application granted granted Critical
Priority to NO20021607A priority patent/NO20021607L/no
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Definitions

  • the present invention is in the field of gene biotechnology and gene therapy and relates to novel virosomes, i.e., positively charged liposomal vesicles containing viral glycoproteins in the membrane, for efficient transfer of genetic material to target locations, a method of manufacture and useful applications thereof.
  • novel virosomes i.e., positively charged liposomal vesicles containing viral glycoproteins in the membrane, for efficient transfer of genetic material to target locations, a method of manufacture and useful applications thereof.
  • the present cationic virosomes are particularly suitable for the specific and unspecific, non-infectious delivery of genes to target cells in vitro and in vivo.
  • Liposomes are widely used as carriers for drug delivery and as protective shelters for short-lived pharmaceutical substances or against (bio)chemical attack by bodily fluids.
  • Liposomes containing reconstituted membrane proteins or parts thereof from viral envelopes are usually called “virosomes” (Sizer et al., Biochemistry 26:5106-5113, 1987). They have been applied for non-specific delivery of various drugs and DNA molecules (Vainstein et al., Methods Enzymol. 101:492-512, 1983). It turned out to be a major drawback that these virosomes fused with the cell membrane of the target cells resulting in an uncontrolled release of the transported material into the cytoplasm of the target cells where the unprotected material was readily attacked by degradative intracellular processes.
  • WO 92/13525 reports that virosomes made of phospholipid bilayer membranes which are targeted with viral spike proteins from influenza virus and with cell-specific markers such as, e.g., monoclonal antibodies, very efficiently fuse with model membranes and animal cells due to a virus-like penetration mechanism by way of receptor-mediated endocytosis. While these virosomes are successfully applied to deliver chemical substances and desired drugs to target locations, they suffer from certain disadvantages with respect to stable incorporation and transfer of charged molecules such as, for instance, negatively charged nucleic acids.
  • Virus mediated gene transfer Genes can be introduced stably and efficiently into mammalian cells by means of retroviral vectors. However, the efficiency of gene transfer to non-replicating cells is very low because retroviruses infect only dividing cells. Further, general safety concerns are associated with the use of retroviral vectors relating to, for instance, the possible activation of oncogenes. Replication-defective adenovirus has become the gene transfer vector-of-choice for a majority of investigators.
  • the adenovirus vector mediated gene delivery involves either the insertion of the desired gene into deleted adenovirus particles or the formation of a complex between the DNA to be inserted and the viral coat of adenovirus by a transferring-polylysine bridge.
  • the drawback of this very efficient system in vivo is an undefined risk of infection or inflammation: Despite the E1 gene deletion that renders the virus defective for replication, the remaining virus genome contains numerous open reading frames encoding viral proteins (Yang et al. 1994; Proc. Natl. Acad. Sci. USA 91, 4407-4411). Expression of viral proteins by transduced cells elicits both humoral and cellular immune responses in the animal and human body and thus, may provoke inflammation and proliferation.
  • HVJ Sendai virus
  • HVJ Sendai virus
  • This method has already been used for gene transfer in vivo to various tissues.
  • cellular uptake of antisense oligonucleotides by HVJ-liposomes was reported (Morishita et al. 1993; J. Cell. Biochem. 17E, 239).
  • a particular disadvantage is, however, that the HVJ-liposomes tend to non-specifically bind to red blood cells.
  • Lipid mediated gene transfer Positively charged liposomes made of cationic lipids appear to be safe, easy to use and efficient for in vitro transfer of DNA and antisense oligonucleotides.
  • the highly negatively charged nucleic acids interact spontaneously with cationic liposomes.
  • a complete formation of DNA-liposome complexes is achieved.
  • due to the lack of fusion peptides and cell-specific markers on the liposomal membrane the in vivo transfection efficiency is very low and the incubation times are long, wherefore high doses have to be administered in order to achieve a desired effect. Consequently, undesired side-effects may occur since there is evidence that large amounts of cationic lipids can exhibit toxic effects in vivo.
  • RNA duplex molecules Small oligonucleotides are currently being tested as therapeutic agents for the treatment of cancer and as antiviral agents. Only one of the two DNA strands is transcribed to synthesize messenger RNA (mRNA). The DNA strand transcribed into RNA is called the coding strand or sense strand. The complementary, non-coding or antisense strand has the same sequence as the mRNA. When the non-coding strand is transcribed, it produces antisense RNA molecules that are able to bind to target (sense) mRNA. Once the antisense RNA is bound to the sense RNA the resulting RNA duplex molecules cannot be translated and the production of the protein is blocked.
  • mRNA messenger RNA
  • antisense oligonucleotides of 18 to 22 bases effectively bind to the mRNA and inhibit mRNA translation. By this mechanism antisense oligonucleotides can stop the proliferation of human cancer cells.
  • Genes that are involved in cancer exert their effect through overexpression of their normal structural proteins. Genes such as c-fos, c-myc, L-myc, N-myc, c-myb, abl, bcr-abl, c-raf, c-erb-2, K-ras may be potential targets for antisense cancer therapy.
  • Antisense oligonucleotides are also an attractive potential alterative to conventional drugs such as, for example, antiviral agents such as, e.g., the antisense oligonucleotides of tat and gag gene of the human immunodeficiency virus (HIV).
  • antiviral agents such as, e.g., the antisense oligonucleotides of tat and gag gene of the human immunodeficiency virus (HIV).
  • Liposomal membranes comprising reconstituted virus envelopes as described in the literature (Stegmann et al.; EMBO J. 6:2651-2659, 1987) may be called virosomes. They usually comprise a phospholipid bilayer containing phosphatidylcholine (PC) and phosphatidylethanolamine (PE) together with viral envelope, e.g., spike proteins embedded in the membrane.
  • PC phosphatidylcholine
  • PE phosphatidylethanolamine
  • viral envelope e.g., spike proteins embedded in the membrane.
  • PC phosphatidylcholine
  • PE phosphatidylethanolamine
  • the conventional methods to incorporate genetic material into PC, PE-virosomes suffer from the drawback of a rather low efficiency of nucleic acid incorporation.
  • the present invention therefore relates to a novel cationic virosome which due to its specific membrane composition may very efficiently be loaded with any desired genetic material comprising long and short chain DNA or RNA, oligodeoxynucleotides, ribonucleotides, peptide nucleic acids (PNA), ribozymes (RNA molecules with enzymatic activities), genes, plasmids and vectors and, thus, convincingly overcomes the drawbacks of the prior art.
  • PNA peptide nucleic acids
  • the invention further relates to a method for the efficient reconstitution of hemagglutinin of influenza virus A, particularly of strain A/Singapore, into substantially unilamellar cationic lipid vesicles resulting in the formation of cationic virosomes with a mean diameter of approximately 120-180 nm and a continuous lipid bilayer, which is substantially free from the disadvantage of leakage seen with many conventional virosome preparations.
  • the structure of the—preferably unilamellar—cationic brayer membrane is such that the hydrophilic, positively charged heads of the lipids are oriented towards the aqueous phase(s) and the hydrophobic fatty acid tails are oriented towards the center of the bilayer. It could be shown by electron microscopy that the reconstituted viral spike proteins (hemagglutinin) are integrated in the lipid bilayer and extend from the surface of the cationic vesicles (FIG. 1 ).
  • FIG. 1 shows a micrograph of DOTAP virosomes with viral spike proteins.
  • FIG. 2 shows the pH-induced fusion activity of octadecyl rhodamine B labeled DOTAP-virosomes with model liposomes.
  • FIG. 3 shows DOTAP-virosomes with encapsulated antisense FITC-OPT incorporated into human small cell lung cancer cells.
  • FIG. 4 and FIG. 5 show the extraordinary uptake and transfection efficiency of antisense-L-myc-DOTAP-virosomes into human small cell lung cancer cells.
  • FIG. 6 shows the incubation of different human small cell lung cancer cells, with Antisense-L-myc virosomes.
  • FIG. 7 a , 7 b show the transfection efficiency of pRSVcat-DOTAP virosomes for Jurkat cells.
  • FIG. 8 Fusion of DOTAP-virosomes with phospholipid-liposomes. Fusion was measured with the R18 assay at 37° C.
  • FIG. 9 Thymidine incorporation into virosome-treated NCI-H209 cells.
  • 75 ⁇ l of virosomes containing 200 picomol of either antisense, sense, or msc FITC-OPT and 625 ⁇ l of fresh medium containing 0.5 ⁇ Ci 14 C-thymidine were added to 5 ⁇ 10 4 cells/ml per well.
  • FIG. 10 Dose-dependent inhibition of thymidine incorporation into NCI-H209 cells upon addition of virosomes containing antisense-L-myc-OPT. NCI-H209 cells were incubated at an initial cell concentration of 1 ⁇ 10 5 per well and per ml. Values are the means ⁇ standard deviations of three experiments
  • FIG. 11 Incubation of different human small cell lung cancer cell lines with 75 ⁇ 1 of antisense-L-myc virosomes. L-myc oncogen expression decreases in the cell lines as indicated: H82 ⁇ H51OA ⁇ H209. The virosomes of lot 1 contained a smaller amount of antisense-L-myc than the ones of lot 2.
  • FIG. 12 Transfection of Sp2 cells by two differently produced virosome preparations.
  • FIG. 13 Transfection of P3/NS1 cells by two differently produced virosome preparations.
  • FIG. 14 Transfection of NIH/3T3 cells by two differently produced virosome preparations.
  • FIGS. 15, 16 , 17 Cell growth of KG1 cells upon treatment with sense and antisense c-myb-DOTAP virosomes. Addition of 25, 50 or 100 ⁇ l of virosome solution containing 18, 36, or 72 pmol OPT, respectively. Values are the means ⁇ standard deviations of three experiments.
  • FIG. 18 Cell growth of CEM-C3 cells upon treatment with DOTAP-virosomes at the addition of 50 ⁇ l of sense and antisense c-myb virosome solution. Values are the means ⁇ standard deviations of three experiments.
  • FIG. 19 Influence of time transfection on the amount of uptaken DNA-plasmid. 5 ⁇ 10 5 cells of human, transformed primary embryonal kidney cell line 293 T were transfected with DOSPER-virosomes and DOSPER-liposomes containing 3 H-labeled plasmid pGreen Lantern.
  • FIG. 20 Influence of time transfection on the amount of uptaken DNA-plasmid. 5 ⁇ 10 5 cells of monkey fibroblast cell line COS-1 were transfected with DOSPER-virosomes and DOSPER-lipsomes containing 3 H-labeled plasmid pGreen Lantern.
  • FIG. 21 Influence of time transfection on the amount of uptaken DNA-plasmid. 5 ⁇ 10 5 cells of human epithelioid carcinoma cell line HeLa were transfected with DOSPER-virosomes and DOSPER-liposomes containing 3 H-labeled plasmid pGreen Lantern.
  • FIG. 22 Influence of time transfection on the amount of uptaken DNA-plasmid. 5 ⁇ 10 5 cells of mouse fibroblast cell line NIH3T3 were transfected with DOSPER-virosomes and DOSPER-liposomes containing 3 H-labeled plasmid pGreen Lantern.
  • FIG. 23 Influence of time transfection on the amount of uptaken DNA-plasmid. 5 ⁇ 10 5 cells of human chronic myelogenous leukemia cell line K562 were transfected with DOSPER-virosomes and DOSPER-liposomes containing 3 H-labeled plasmid pGreen Lantern.
  • FIG. 24 Influence of time transfection on the amount of uptaken DNA-plasmid. 5 ⁇ 10 5 cells of mouse myeloma cell line P3 were transfected with DOSPER-virosomes and DOSPER-liposomes containing 3 H-labeled plasmid pGreen Lantern.
  • FIG. 25 Influence of time transfection on the amount of uptaken DNA-plasmid. 5 ⁇ 10 5 cells of human epithelioid carcinoma cell line HeLa were transfected with DOSPER-virosomes and DOTAP-virosomes containing 3 H-labeled plasmid pGreen Lantern.
  • FIG. 26 Influence of time transfection on the amount of uptaken DNA-plasmid. 5 ⁇ 10 5 cells of human chronic myelogenous leukemia cell line K562 were transfected with DOSPER-virosomes and DOTAP-virosomes containing 3 H-labeled plasmid pGreen Lantern.
  • the lipid composition of the vesicle membrane comprises cationic and/or polycationic lipids together with phosphatidylethanolamine and optionally other phospholipids such as phosphatidylcholine.
  • lipid composition of the membrane comprising—based on total lipids—10% by weight or less, preferably 1-10%, of phosphatidylethanolamine together with 90% by weight or more, preferably 90-99%, of other lipids including the cationic and/or polycationic lipids, and optionally further including phosphatidylcholine. If present, phosphatidylcholine should be present in an amount of, for example, 5-50% by weight, based on total lipids.
  • PE phosphatidylethanolamine
  • the present invention also relates to the irreversible covalent linkage of cell-specific markers to the cationic virosomes including but not being limited to monoclonal antibodies, antibody fragments such as F(ab′) 2 and Fab′ fragments, cytokines, and/or growth factors, useful for a selective detection and binding of target cells. They are linked to the vesicle membrane such that they extend to the exterior and exert essentially full functional activity with respect to receptor detection and binding.
  • the markers are coupled to preformed phosphatidylethanolamine-crosslinker molecules such as, for example, N-[4-(p-maleimido-phenylbutyryl]-phosphatidylethanolamine (MPB.PE) in the presence of a detergent.
  • MPB.PE N-[4-(p-maleimido-phenylbutyryl]-phosphatidylethanolamine
  • conjugated markers e.g., marker-MPB.PE
  • MPB.PE unconjugated phosphatidylethanolamine-crosslinker molecules
  • antibody fragments F(ab′) 2 and Fab′ instead of whole antibody molecules as cell-specific markers is particularly advantageous, because they are far less immunogenic than the whole antibody.
  • the absence of the Fc domain eliminates a range of undesired Fc-mediated biological and immunological activities such as, for example, complement activation via the classical pathway and acute humoral responses eventually resulting-amongst others—in the clearance of attached virosomes from the target cell surface via interaction between the antibody and its Fc-receptor on the target cell.
  • the present cationic virosomes usually need not fuse with or destabilize the plasma cell membrane to enter the cytoplasm. They are capable of entering the host cells via a two step mechanism: 1. attachment and 2. penetration. In the first step they bind via the fusion peptides (e.g. hemagglutinin) and/or the cell-specific markers to cell receptors, particularly to membrane glycoproteins or glycolipids with a terminal sialic acid, and are then very efficiently incorporated by receptor-mediated endocytosis.
  • fusion peptides e.g. hemagglutinin
  • cell-specific markers e.g., antibody fragments
  • these markers will additionally recognize antigenic structures on the target cell surface, resulting in an attachment by two different binding mechanisms.
  • the present cell-specific virosomes exert a selectivity for various cell types owing to their cell-specific markers on the membrane and, simultaneously, a high capability for cell penetration by endocytosis owing to the viral fusion peptide, e.g., hemagglutinin.
  • Virosomes with Fab′ fragments that recognize tumor-associated antigens such as TAG72, CEA, 17-1A, CA 19-9 or leukemia-associated antigens such as CD10 (CALLA Common Acute Lymphocytic Leukemia Antigen) and CD20 will bind selectively to tumor or leukemia cells carrying the mentioned antigens on their cell surface.
  • tumor-associated antigens such as TAG72, CEA, 17-1A, CA 19-9 or leukemia-associated antigens
  • CD20 will bind selectively to tumor or leukemia cells carrying the mentioned antigens on their cell surface.
  • the virosomes In the second step, when entering the host cells via receptor-mediated endocytosis the virosomes get entrapped in endosomes. Subsequently, the pH within the endosomes decreases to about pH 5-6, which activates the hemagglutinin fusion peptide and triggers the fusion of the virosomal membrane with the endosomal membrane. The membrane fusion reaction opens the lipid envelope of the virosomes and liberates the entrapped genetic material into the cytosol. This mechanism considerably improves the chances of the transferred genetic material to reach the nucleus before getting cleared by digestive degradation and/or exocytosis.
  • An objective of the present invention is to provide positively charged lipid vesicles comprising cationic or polycationic lipids and an internal—usually aqueous—space, and further comprising at least one viral fusion peptide embedded or integrated in or covalently linked to the vesicle membrane.
  • the vesicle preferably also comprises at least one cell-specific marker on the membrane. It is a further object of the present invention to provide vesicles having full biological fusion activity, i.e., having essentially the same fusion activity as intact influenza virus.
  • the fusion peptide is a viral-glycoprotein such as hemagglutinin or a derivative thereof, or a synthetic fusion peptide being capable of inducing a rapid fusion of said vesicles with the endosomal membranes of the target cells after endocytosis.
  • novel vesicles or virosomes are particularly useful to transfer any desired genetic material to target locations, in particular to animal and human cells and tissues in vitro and in vivo. It is emphasized that the novel virosomes are not only able to penetrate proliferating, i.e., replicating cells but also non-proliferating, i.e., resting cells, which feature makes them widely applicable in the fields of biosciences, pharmacology and medicine, both as a research and/or diagnostic tool and as a medicament.
  • the present virosomes may be part of a pharmaceutical composition which further comprises usual additives and pharmaceutically suitable carriers. It is preferred that the pharmaceutical composition is prepared as an injection solution, but other forms of preparation, e.g., emulsions, cremes, gels, ointments, for topical or systemic administration may be advantageous for some applications.
  • the present invention uses the present virosomes for the manufacture of a pharmaceutical composition suitable for the prophylactic and/or therapeutic treatment of animal or human individuals who may benefit from such treatment. It is another objective of the present invention to use the present virosomes for the manufacture of a diagnostic kit for in vitro and in vivo applications.
  • the present vesicles are obtained by a process comprising an efficient reconstitution of hemagglutinin (HA) of influenza virus A. Accordingly, it is also an object of the present invention to teach a method of preparing cationic virosomes. In a preferred embodiment, the method further comprises the steps of incorporating genetic material into the cationic lipid vesicles. Basically, the method of preparation comprises the following steps:
  • a non-ionic detergent preferably octaethyleneglycol mono-n-dodecylether (OEG, C 12 E 8 ), together with—preferably purified—viral spike glycoproteins, genetic material desired or delivery and optionally preformed complex molecules made of phosphatidylethanolamine, crosslinker and cell-specific marker; and
  • a suitable bifunctional crosslinker is applied to link the cell-specific marker irreversibly to the vesicle membrane.
  • the cell-specific marker which is directed to a cell-receptor responsible for the selective binding of the virosome to the cell, is bound to the crosslinker in such a manner that it is still fully biologically active.
  • the crosslinker be employed in the form of a preformed molecule-complex wherein the crosslinker is covalently bound to either phosphatidylethanolamine or to both phosphatidylethanolamine and a cell-specific marker.
  • the encapsulated material is released to the cytosol of a target cell mainly upon decrease of the endosomal pH (as outlined above).
  • Such controlled release on one hand prolongs the residence time of the delivered material within the target cell and on the other hand avoids an undesired long stay of the virosomes inside the endosomes and therewith reduces the danger of unspecific degradation of the valuable substances transported by the virosomes.
  • the present invention refers to vesicles where the membrane lipids additionally comprise phosphatidylcholine and phosphatidylethanolamine, which further improves the possibilities of specific virosome design and/or facilitates the anchoring of fusion peptides and/or cell-specific markers to the membrane.
  • fusion peptide refers to peptides or proteins capable of inducing and/or promoting a fusion reaction between the virosome membrane and a lipid membrane of the target cell. In most embodiments, it refers to viral spike glycoproteins containing the fusion peptide, particularly to the complete hemagglutinin trimer of viral surface spikes, a monomer thereof, or one or both cleaved subunits, the glycopeptides HA1 and HA2, containing the functional fusion peptide. In another embodiment of the present invention the term refers to the pure fusion peptide itself, either isolated from natural sources or synthetically produced.
  • these polypeptides containing the fusion peptide refer to influenza hemagglutinins, especially the one of the A-H 1 N 1 subtype.
  • the synthetic fusion peptides are preferably selected from the amino acid sequences listed in Table 1 below, wherein the amino acids are identified by their corresponding one letter codes and wherein the sequences are represented by SEQ ID NOS: 1-16 in number order from top to bottom (see also Example 6 and FIG. 2 of WO 92/13525).
  • hemagglutinins from other viruses may also be suitably used as fusion peptides (proteins) for the instant virosomes as long as they exert substantially the same pH-mediated cell penetration mechanism as the influenza hemagglutinin.
  • fusion peptides proteins
  • hemagglutinins include, for example, rhabdovirus, parainfluenza virus type III, Semliki Forest virus and togavirus, as disclosed in U.S. Ser. No. 07/930,593, now U.S. Pat. No. 6,040,167 (assignee: NIKA HEALTH PRODUCTS LTD.), incorporated herein by reference.
  • crosslinker refers to an organic heterobifunctional molecule capable of linking to the surface of vesicles prepared according to this invention and capable of binding polypeptides.
  • this molecule contains a N-hydroxysuccinimide group for coupling to the amino group of phosphatidylethanolamine and a maleimide group for conjugation of monoclonal antibody fragments, such as succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate, m-maleimidobenzoyl-N-hydroxysuccinimide ester, m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester, succinimidyl 4(p-maleimidophenyl)-butyrate, sulfosuccinimidyl 4(p-maleimidophenyl)butyrate; or it contains a N-hydroxysuccinimide group and a photoreactive
  • crosslinker be used in the form of a preformed molecule complex of crosslinker and lipid, notably of crosslinker and phosphatidylethanolamine, or of lipid plus crosslinker plus cell-specific marker.
  • cell-specific protein or marker refers to a protein capable of linking to the crosslinker or crosslinker-lipid complex, respectively, and further being capable of binding to the receptor of target cells.
  • this molecule refers to a cell receptor-specific compound such as a monoclonal antibody, an antibody fragment, a cytokine or a growth factor.
  • the cell-specific marker provides for selective detection and binding of target cells and thus improves the action of the fusion peptide concomitantly present in the virosomal membrane.
  • the preferred antibody fragments comprise the F(ab′) 2 and Fab′ fragments, while the cell-specific markers further comprise interleukins and other cytokines, particularly the ones listed in Table 2 below.
  • cationic lipid refers to an organic molecule that contains a cationic component and a nonpolar tail, a so-called head-to-tail amphiphile, such as N-[(1,2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) (Felgner et al.; Proc Natl Acad USA 84:7413-7417, 1987), N-[1,2,3-dioleoyloxy)-propyl]-N,N,N-trimethylammoniummethylsulfate (DOTAP); or N-t-butyl-N′-tetradecyl-3-tetradecylaminopropionamidine (Ruysschaert et al.; Biochem. Biophys. Res. Commun. 203:1622-1628, 1994). Unless explicitly mentioned otherwise, the term also includes the below defined polycationic lipids.
  • DOTMA N-[(1,2,
  • polycationic lipid refers to an organic molecule that contains a polycationic component and a nonpolar tail such as the lipospermine: 1,3-dipalmitoyl-2-phosphatidylethanolamido-spermine (DPPES) and dioctadecylamidoglycyl spermine (DOGS) (Behr et al.; Proc. Natl. Acad.
  • DPES 1,3-dipalmitoyl-2-phosphatidylethanolamido-spermine
  • DOGS dioctadecylamidoglycyl spermine
  • DOSPA 2,3-dioleoyloxy-N-[2(sperminecarboxamido) ethyl]-N,N-dimethyl-1-propaneaminium trifluoroacetate
  • DOSPA 1,3-dioleoyloxy-2-(6-carboxy-spermyl)-propylamide
  • DOSPER 1,3-dioleoyloxy-2-(6-carboxy-spermyl)-propylamide
  • THDOB N,N,N′,N′-tetramethyl-N,N′-bis(2-hydroxyethyl)-2,3-dioleoyloxy-1,4-butanediammonium iodide
  • the lipids preferably comprise one or more natural or synthetic lipids that are positively charged.
  • positively charged is meant that the lipids have a positive net charge at physiological pH.
  • positively charged lipids, membranes or virosomes shall mean lipids, membranes or virosomes that have a positive net charge at physiological pH. It is not intended to include neutral lipids, e.g., phospholipids of the zwitterionic-type, which have positively charged areas within the molecule but which do not exhibit any net charge at physiological pH due to the presence of negatively charged parts of the molecule which stoichiometrically offset the positive charges.
  • nucleic acid or “genetic material” as used herein comprise short chain DNA or RNA, deoxyribonucleotides, oligodeoxyribonucleotides, oligodeoxyribonucleotide selenoates, oligodeoxyribonucleotide phosphorothioates (OPTs), oligodeoxyribonucleotide phosphoramidates, oligodeoxyribonucleotide methylphosphonates, peptide nucleic acids (PNAs), ribonucleotides, oligoribonucleotides, oligoribonucleotide phosphorothioates, 2′-Ome-oligoribonucleotide phosphates, 2′-Ome-oligoribonucleotide phosphorothioates, ribozymes (RNA molecules with enzymatic activities), genes, plasmids and vectors (cloning vehicles).
  • OPTs oligodeoxy
  • viral proteins refers—in its simplest form—to liposomal vesicles with a bilayer membrane comprising cationic lipids and an internal—preferably aqueous—space, wherein the membrane further contains viral proteins, in particular viral glycoproteins.
  • the viral proteins comprise at least one fusogenic peptide or protein having full biological fusion activity, particularly the spike glycoprotein hemagglutinin and/or neuraminidase of influenza A (e.g., A/Singapore) virus.
  • influenza A e.g., A/Singapore
  • the membrane lipids comprise the cationic lipids defined above but may optionally further comprise other natural and/or synthetic lipids, preferably phospholipids such as phosphatidylcholine (PC) and phosphatidylethanolamine (PE).
  • PC phosphatidylcholine
  • PE phosphatidylethanolamine
  • the cationic virosomes of the present invention may in many cases—notably for in vitro cell culture experiments—successfully be applied without cell-specific markers on the membrane, it is particularly preferred for in vivo applications that they further comprise at least one cell-specific marker on the membrane as hereinbefore defined.
  • the mean diameter of the vesicles is in the range of 120-180 nm, as determined by electron microscopy and dynamic light scattering.
  • full (biological) fusion activity shall express that the virosomes of the present invention comprising reconstituted viral proteins in the vesicle membrane have essentially the same fusion activity towards target cells as the intact virus from which they are usually reconstituted.
  • the comparison of the cationic virosomes, fusogenicity is drawn to intact influenza A virus.
  • the fusion activity is measured according to known procedures, particularly as reported by Hoekstra et al. (Biochemistry 23:5675-5681,1984), or Luscher et al. (Arch. Virol. 130:317-326, 1993).
  • antisense technology can therapeutically or prophylactically be applied to a patient in need thereof a number of technical problems, particularly relating to the development of a suitable carrier system, need be resolved beforehand.
  • genetic material such as, e.g., antisense oligonucleotides
  • the cationic virosomes of the present invention as carriers for genetic material these problems can be successfully overcome and undesired side effects due to toxicity can be prevented or at least considerably decreased.
  • This beneficial effect is achieved because the present cationic virosomes have—compared to liposomes or virosomes known hitherto—a far higher activity and efficiency of up to a factor of 1,000-20,000 for the transfer of entrapped genetic material such as antisense oligonucleotides into target cells.
  • Hemagglutinin (HA) from the A/Singapore/6/86 strain of influenza virus was isolated as described by Skehel and Schild (1971), Proc. Natl. Acad. Sci. USA 79:968-972. In short, virus was grown in the allantoic cavity of hen eggs, and was purified twice by ultracentrifugation in a sucrose gradient.
  • Purified virus was stabilized in a buffer containing 7.9 mg/ml NaCl, 4.4 mg/ml trisodiumcitrate-2H 2 O, 2.1 mg/ml 2-morpholinoethane sulfonic acid, and 1.2 mg/ml N-hydroxyethyl-piperazine-N′-2-ethane sulfonic acid pH 7.3. 53 ml of the virus suspension containing 345 ⁇ g HA per ml were pelletted by ultracentrifugation at 100,000 ⁇ g for 10 minutes.
  • the solution was sterilized by passage through a 0.2 ⁇ m filter and then transferred to a glass container containing 1.15 g of sterile microcarrier beads, preferably Biobeads SM-2.
  • the container was shaken for 1 hour by using a shaker REAX2 from Heidolph (Kelheim, Germany). When necessary, this procedure was repeated up to three times with 0.58 mg of Biobeads. After these procedures a slightly transparent solution of DOTAP virosomes was obtained.
  • DOTAP-PC virosomes 3 mg of DOTAP and 3 mg of PC were added to the supernatant containing 6 mg HA, and dissolved. The subsequent steps were the same as described for the DOTAP virosomes.
  • One possibility of preparing cationic virosomes carrying synthetic fusion peptides in the membrane comprises the following steps:
  • PE phosphatidylethanolamine
  • GMBS crosslinker N-[ ⁇ -maleimidobutyryloxylsucccinimide ester (GMBS) in a reaction PE+GMBS ⁇ MBS-PE+N-Hydroxysuccinimid, as described by Martin et al., Irreversible coupling of immunoglobulin fragments to preformed vesicles; J. Biol. Chem. 257:286-288 (1982).
  • lipid vesicles with activated PE wherein 20% Phosphatidylcholine, 70% DOTAP and 10% GMB-PE are dissolved in a buffered detergent solution as described above for the HA containing DOTAP virosomes.
  • the subsequent steps of preparing the lipid vesicles are the same as described above for the DOTAP virosomes.
  • lipid vesicles a solution of freshly prepared lipid vesicles in a buffer (40 mM citric acid, 35 mM disodium phosphate, 100 mM NaCl, and 2 mM EDTA, pH 5.5) is mixed with the peptide solution in the same buffer. The mixture is gently stirred under nitrogen atmosphere overnight at 4° C. Lipid vesicles are separated from unconjugated peptides by gel filtration on a High Load Superdex 200 column.
  • a buffer 40 mM citric acid, 35 mM disodium phosphate, 100 mM NaCl, and 2 mM EDTA, pH 5.5
  • the fusion peptides may also be coupled to the lipid vesicles my means of preformed PE-crosslinker-peptide complexes as described below in this example for the Fab′ fragments.
  • the antisense and sense oligodeoxyribonucleotide phosphorothioates (OPTs) of the L-myc gene were used as an example for the demonstration of the high efficiency of cationic virosomes in transfection.
  • 5′-FITC-OPTs were synthesized via phosphoramidite chemistry (Microsynth GmbH, Balgach, Switzerland).
  • the pentadecamer (5′-FITC-GTAGTCCATGTCCGC-3′) and the pentadecamer (5′-FITC-GCGGACATGGACTAC-3′) were used as the antisense OPT and sense OPT, respectively.
  • a mixed sequence control (msc) OPT consisting of the same length of nucleotides as antisense and sense OPTs was synthesized.
  • FITC-OPTs were dissolved and the solutions were then treated by sonication for 2 minutes at 26° C.
  • Non-encapsulated FITC-OPTs were separated from the virosomes by gel filtration on a High Load Superdex 200 column (Pharmacia, Sweden). The column was equilibrated with sterile PBS. The void volume fractions containing the DOTAP virosomes with encapsulated FITC-OPT were eluted with PBS and collected. Virosome-entrapped FITC-OPT concentrations were determined fluorometrically after the virosomes were fully dissolved in 0.1 M NaOH containing 0.1% (v/v) Triton X-100. For calibration of the fluorescence scale the fluorescence of empty DOTAP-virosomes that were dissolved in the above detergent solution was set to zero.
  • the solutions prepared as described above were added to the solutions for the preparation of DOTAP virosomes.
  • the Fab′-MPB.PE molecules are inserted into the lipid bilayer during the formation of virosomes.
  • Micrographs of DOTAP virosomes confirm the preferred unilamellar structure of the vesicles with an average diameter of approximately 120 to 180 nm as determined by laser light scattering.
  • the HA protein spikes of the influenza virus are clearly visible (FIG. 1 ).
  • the fusion activity of the present DOTAP virosomes was measured by the quantitative assay based on fluorescence dequenching described by Hoekstra et al. (1984), Biochemistry 23:5675-5681 and L. Lüscher et al. (1993), Arch. Virol. 130:317-326.
  • the fluorescent probe octadecyl rhodamine B chloride (R18) (obtained from Molecular Probes Inc., Eugene, USA) was inserted at high densities into the membrane of DOTAP virosomes by adding the buffered OEG (C 12 E 8 ) solution containing DOTAP and HA to a thin dry film of the fluorescent probe, followed by shaking for 5 to 10 minutes for dissolving the probe, then continuing as described above under “Preparation of a cationic lipid vesicle . . . ”.
  • FIG. 2 shows the pH-induced fusion reaction of DOTAP virosomes expressed as percent of fluorescence dequenching (% FDQ).
  • Human small cell lung cancer cells (ATCC-NCI-H209 American Type Culture Collection, Rockville, USA) were cultured in 24-well Costar plates at an initial concentration of 1 ⁇ 10 5 per well and per ml. After an incubation of 24 hours, medium was removed and 625 ⁇ l of fresh medium containing 0.5 ⁇ Ci 14 C-thymidine (prepared from (2- 14 CI thymidine, 52.0 mCi/mmol; Amersham, England) and 75 ⁇ l of DOTAP virosomes containing 0.2 nmol of either antisense, sense, or msc FITC-OPTs were added. The cultures were gently shaken at very slow agitation for 1 hr at 37° C. and then transferred to the incubator.
  • 0.5 ⁇ Ci 14 C-thymidine prepared from (2- 14 CI thymidine, 52.0 mCi/mmol; Amersham, England
  • DOTAP virosomes containing 0.2 nmol of either anti
  • FIGS. 4 and 5 clearly demonstrate the extraordinary uptake and transfection efficiency of antisense-L-myc-DOTAP virosomes.
  • FIG. 6 demonstrates that calls that do not express L-myc are not influenced or inhibited by the antisense-L-myc virosomes. Also, empty virosomes did not show any effects on cancer cells and normal cells. It appears therefore that an anti-cancer therapy with antisense OPT encapsulated in the present virosomes may have a great potential, particularly because of their lack of the hereinbefore mentioned disadvantages of conventional cationic liposomes.
  • pcDNA3 (Invitrogen Corporation, San Diego, USA) is a 5.4 kb vector designed for high-level stable and transient expression in eukaryotic hosts. HA was isolated and purified as described in Example 1.
  • OEG pcDNA3-IL-6
  • the obtained solution comprising the pcDNA-IL-6 loaded DOTAP virosomes was diluted 1:1000 with PBS. 20 ⁇ l and 50 ⁇ l of this solution containing 1 ng and 2.5 ng pcDNA-IL-6, respectively, were added to 2 ⁇ 10 6 myeloma cells (P3/NSI/1-Ag4-1; American Type Culture Collection, Rockville, USA). After 48 h incubation the supernatants of the cell cultures were tested for human IL-6 by an ELISA assay. A content of 20 to 45 pg IL-6 per ml was measured.
  • IL-6 was found in myeloma cell cultures transfected with conventional DOTAP liposomes (which are devoid of viral fusion peptides) containing the same amount of pcDNA-IL-6 as the DOTAP virosomes. In order to obtain the same transfection results as with the pcDNA-IL-6 loaded DOTAP virosomes it was necessary to increase the amount of the pcDNA-IL-6 loaded DOTAP liposomes by a factor of one thousand 1000.
  • the expression vector pRSVcat (from ATCC, Rockville, USA) contains the CAT gene which codes for the chloramphenicol acetyltransferase (CAT). The enzyme catalyzes the transfer of an acetyl group from acetyl-CoA to the 3′-hydroxy position of chloramphenicol. CAT vectors are useful for monitoring transfection efficiency in general.
  • pRSVcat was encapsulated into DOTAP virosomes under the conditions described in Example 2.
  • Jurkat cells (10 6 cells/ml) were incubated with different amounts of pRSVcat-loaded DOTAP virosomes (0.0001 ⁇ l-25 ⁇ l). After 48 hours incubation at 37° C. the CAT activity in the Jurkat cells was measured by the CAT-ELISA assay (Boehringer Mannheim, Germany).
  • FIGS. 7 a and 7 b demonstrate that a maximum transfection is achieved by addition of 0.01 ⁇ l of DOTAP virosomes. Contrary to the aforementioned, the addition of 0.01 ⁇ l of pRSVcat-loaded DOTAP liposomes to Jurkat cells under the same incubation conditions did not result in any detectable CAT activity.
  • Attachment involves binding of the virosomes via HA to the cell receptors which are membrane glycoproteins or glycolipids with a terminal sialic acid.
  • Fab′ fragments will additionally recognize antigenic structures on the target cell surface, resulting in an attachment to target cells by two different binding mechanisms.
  • specific virosomes exert a selectivity for special cell types.
  • Virosomes with Fab′ fragments that recognize tumor associated antigens such as TAG72, CEA, 17-1A, CA19-9 or leukemia associated antigens such as CD10 (CALLA) and CD20 will bind selectively to tumor or leukemia cells carrying the mentioned antigens on their cell surface.
  • the hemagglutinin glycoproteins are carefully isolated and purified. There is no inactivation either by proteolytic digestion or by reduction of its intramolecular disulfide (—S—S—) bonds.
  • Penetration involves entry of virosomes into the cells by receptor-mediated endocytosis.
  • the virosomes get trapped in endosomes.
  • the acidic pH (5-6) within the endosomes triggers fusion of the virosomal membrane with the endosomal membrane.
  • the fusion is mediated by the viral spike glycoprotein hemagglutinin (HA).
  • HA hemagglutinin
  • Virosomes were labeled with the fluorescent probe octadecyl rhodamine B (R18) and the fusion activity of HA was monitored as fluorescence dequenching due to the dilution of the probe from the virosomal into a liposomal target membrane.
  • FIG. 8 shows the fluorescence observed upon addition of DOTAP-virosomes, labeled with R18, to phospholipid-liposomes. The fluorescence started to increase rapidly indicating an intact HA mediated fusion.
  • the uptake of virosomes was measured by incubation of cells with 14 C-labeled virosomes.
  • P3/NS1 cells at a concentration of 1 ⁇ 10 5 /ml were incubated with 40 ⁇ l of virosomes at 37° C. for 5, 10, 15, 20 and 30 minutes. After washing, the cells were lysed and the amount of 14 C-label virosomes was measured.
  • Table 3 the cellular uptake is very fast: During the first five minutes 10% of the virosomes were incorporated. Longer incubation times did not enhance the uptake any further. 1 ml of virosome solution contained approximately 10 11 -10 12 virosomes, hence 4,000-40,000 virosomes per cell were incorporated within 5 minutes.
  • ODN oligodeoxynucleotides
  • Antisense ODN have a great potential as therapeutic agents. Many preclinical animal studies as well as clinical trials of Phases I-III have shown that antisense ODN directed against oncogenes and viral genes are therapeutically active.
  • virosomes with a positively charged lipid bilayer were developed for transfer of genetic material.
  • the positively charged lipid bilayer interacts with nucleic acids and causes them to concentrate within the vesicles formed.
  • the L-myc gene first discovered in a small cell lung cancer (SCLC) cell line, is frequently amplified and overexpressed in SCLC.
  • 5′-FITC-phosphorothioate oligodeoxyribonucleotides (OPT) were synthesized via phosphoramidite chemistry (Microsynth GmbH, Balgach, Switzerland).
  • the pentadecamer (5′-FITC-GTAGTCCATGTCCGC-3′) and the pentadecamer (5′-FITC-GCGGACATGGACTAC-3′) were used as the antisense OPT and sense OPT, respectively.
  • a mixed sequence control (msc) OPT consisting of the same length of nucleotides as antisense and sense OPT was synthesized.
  • the antisense OPT covering the translational initiation site acts by inhibiting ribosomal translation of the target mRNA.
  • Antisense-L-myc-phosphorothioate oligodeoxyribonucleotides were encapsulated into the virosomes.
  • the antiproliferative effect of virosome-encapsulated L-myc antisense DNA in the SCLC cell lines H209, H510, and H82 was evaluated.
  • Antisense-L-myc virosomes were added to the cells of human small cell lung cancer cell lines.
  • Sense-L-myc virosomes and msc (mixed sequence control)-virosomes were used as controls (FIG. 9 ).
  • Antisense-L-myc virosomes were 20,000-fold more active than non-encapsulated antisense OPT. To induce the same effects as seen in FIG. 10 concentrations of non-encapsulated L-myc-antisense OPT in the range of micromoles had to be added to the cell cultures. Hence, cationic virosomes are far more efficient in the delivery of ODN than the cellular uptake of nonencapsulated ODN and also more efficient than cationic liposomes.
  • Susceptibility genes such as herpes simplex virus thymidine kinase (HSV-TK) genes (Moolten F L; Cancer Res.
  • genes which target the immune system to eliminate cancer cells such as cytokine genes (Tepper R I et al.; Cell 57:503-512, 1989), genes coding for costimulatory molecules (Townsend S E et al.; Science 259:368-370, 1993), foreign histocompatibility genes (Plautz G E et al.; Proc Natl Acad Sci USA 90: 4645-4649, 1993); and replacement of wild-type tumor suppressor genes such as p53 (Chen P L et al.; Science 250:1576-1580, 1990).
  • the typical transfection efficiencies by using commercially available lipids are between 5-50%. Not only provide virosomes higher transfection efficiency than commercially available liposomes but the entrapment of DNA into virosomes results also in stable transformation of cells.
  • IL-6 Human interleukin 6 gene was cloned into the polylinker site of pcDNA3, a 5.4 kb vector designed for high-level stable and transient expression in eukaryotic hosts.
  • the vector contains the neomycin resistance marker, expressed from the SV40 early promoter for the selection of stable transformants in the presence of G418.
  • Encapsulation of the vector was performed by 3 different methods:
  • Dialysis Plasmids were encapsulated during formation of virosomes. Detergent Octyl-POE (from Alexis Corp., Laeufelfingen, Switzerland) was removed by dialysis.
  • Biobeads Plasmids were encapsulated during formation of virosomes. Detergent OEG was removed by Biobeads.
  • Sp2/0-Ag14 cells Hybrid, non-secreting, mouse; ID-No: ATCC CRL-1581; herein termed Sp2
  • P3/NSI/1-Ag4-1 cells Non-secreting myeloma, mouse; ID-No: ATCC TIB-18; herein termed P3/NS1
  • NIH/3T3 cells Embryo, contract-inhibited, NIH Swiss mouse; ID-No: ATCC CRL-1658
  • Transfected Sp2 and P3/NS1 cells were selected twice by G418. After 2 months of culturing the production of IL-6 was measured again. The values are listed in Table 4.
  • Sp2 Pellets Dialysis 2.25 ⁇ 10 6 1.13 ⁇ 10 7 >1200 >6600 >584 5.5 ml buffer Biobeads 1.8 ⁇ 10 6 9.5 ⁇ 10 6 232 1044 110 in 4.5 ml buffer Ultrasoni- 2.8 ⁇ 10 6 1.37 ⁇ 10 7 680 4760 347 cation 7 ml buffer Sp2 Super- Dialysis 5 ml supern. 268 1340 119 natant Biobeads 5.2 ml supern. 8 42 4.4 Ultrasoni- 4.9 ml supern. 651 3190 233 cation
  • the volume of lysis buffer added to the cell pellets was adjusted so that a cell number of ca. 2 ⁇ 10 6 per ml was obtained.
  • the most common genetic abnormality in human leukemias is the Philadelphia Chromosome (Ph 1 ) translocation.
  • the translocation of the protooncogene abl from chromosome 9 to the breakpoint cluster region (bcr) on chromosome 22 results in the formation of bcr-abl hybrid genes.
  • the abl protooncogene normally encodes a protein with tyrosine kinase activity which is augmented in cells carrying bcr-abl hybrid genes.
  • the bcr-abl transcripts are found in the vast majority of chronic myelogenous leukemia (CML) patients and in Ph 1 acute lymphocytic leukemia patients.
  • CML chronic myelogenous leukemia
  • Ph 1 acute lymphocytic leukemia patients The targeting of bcr-abl genes in CML is clearly the most rational therapeutic procedure.
  • Synthetic ODN complementary to the junction of bcr-abl transcripts produced from the splicing of either the second or third exon of the bcr gene to the second exon of c-abl were shown to suppress Philadelphia 1 leukemic cell proliferation in vitro and to spare the growth of normal marrow progenitors (Szczylik C et al.; Science 253:562-565, 1991).
  • the bcr-abl antisense therapy is restricted to CML patients.
  • Myb the encoded product of the protooncogene c-myb, functions as a DNA binding specific transcription factor. It is preferentially expressed in hematopoietic cells and is required for hematopoietic cell proliferation.
  • CRF-CEM T-cell leukemia line
  • Purging of bone marrow is used as a component in the treatment of several neoplasms, including acute and chronic leukemias.
  • marrow is cleansed of leukemic cells by a variety of agents such as immunologic reagents and chemotherapeutic drugs.
  • Virosome encapsulated ODN targeted against one oncogene that confers a growth advantage to leukemic cells will prove therapeutically useful and, most important, more selective than conventional chemotherapeutic agents in eliminating leukemic cells while sparing normal progenitor cells.
  • Sense and antisense OPT corresponding to c-myb codons 2-9 were prepared.
  • the sense and antisense c-myb sequences were 5′-GCCCGAAGACCCCGGCAC-3′ (SEQ ID NO: 18) and 5′-TGTGCCGGGGTCTTCGGGC-3′ (SEQ ID NO:19), respectively.
  • Encapsulation of OPT into DOTAP-virosomes was performed by the same method used for L-myc DOTAP virosomes.
  • the human myeloid leukemia cell line KG-1 and the human acute lymphoblastic leukemia cell line CEM-C3 were exposed to sense and antisense c-myb virosomes.
  • KG-1 cells Proliferation of KG-1 cells is dependent on the protooncogene myb gene product, whereas CEM-C3 cells are not dependent on the product of c-myb gene.
  • KG-1 cells were incubated with 25, 50, and 100 ⁇ l of sense and antisense c-myb virosomes containing 18, 36, and 72 pmol of sense and antisense OPT, respectively. The number of cells was determined at days 2, 3 and 4.
  • the plasmid pGEEN LANTERNTM-I (GIBCOBRL) was produced in presence of 3 H-methylthymidine. 33 ⁇ g of the labeled plasmid DNA were encapsulated into DOSPER-virosomes and 11.7 ⁇ g into DOSPER-liposomes.
  • the lipid bilayer of the DOSPER-virosomes consists of 25% of DOSPER and 75% of PC (phosphatidylcholine). It is impossible to produce DOSPER-virosomes with a 100% DOSPER bilayer. In particular, it has been found that if the concentration of DOSPER in the reaction mixture is more than, for example, 30%, virosomes may not form.
  • FIGS. 19-24 show clearly that DOSPER-virosomes are superior in transfection to DOSPER-liposomes for all cell types and for all incubation times. Longer incubation times of 6 and 24 h with DOSPER-liposomes only resulted in very minimal increases of DNA uptake, whereas longer incubation times with DOSPER-virosomes led to considerably higher DNA uptake. This result suggests that the HA-mediated uptake of virosomes is far more efficient than the uptake induced by DOSPER-liposomes without the help of any viral binding ligands to cell receptors.
  • FIGS. 25 and 26 demonstrate that the transfection efficiency of DOTAP-virosomes is lower than that of DOSPER-virosomes.
  • encapsulation of plasmid into virosomes containing DOSPER may lead to higher amounts of useful virosomes.
  • encapsulation of plasmid into DOTAP-virosomes may result in a high number of defective vesicles with low transfection potential.
  • a second hypothesis would implicate an enhancing effect of DOSPER during binding of the virosomes to the cell membrane, a viewpoint we cannot exclude.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Saccharide Compounds (AREA)
US09/414,872 1996-05-08 1999-10-08 Cationic virosomes as transfer system for genetic material Expired - Fee Related US6210708B1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
HU0202809A HUP0202809A2 (hu) 1999-10-08 2000-09-29 Kationos DOSPER-viroszómák
CZ20021216A CZ20021216A3 (cs) 1999-10-08 2000-09-29 Lipidové váčky obsahující DOSPER
DK00967824T DK1217990T3 (da) 1999-10-08 2000-09-29 Kationiske DOSPER-virosomer
EP00967824A EP1217990B1 (en) 1999-10-08 2000-09-29 Cationic dosper virosomes
KR1020027004325A KR100869195B1 (ko) 1999-10-08 2000-09-29 양이온성 ｄｏｓｐｅｒ 비로솜
PL00355231A PL355231A1 (en) 1999-10-08 2000-09-29 Cationic dosper virosomes
CA002388053A CA2388053A1 (en) 1999-10-08 2000-09-29 Cationic dosper virosomes
DE60008006T DE60008006T2 (de) 1999-10-08 2000-09-29 Kationische dosper virosomen
PCT/EP2000/009540 WO2001026628A1 (en) 1999-10-08 2000-09-29 Cationic dosper virosomes
AU77850/00A AU778399B2 (en) 1999-10-08 2000-09-29 Cationic DOSPER virosomes
JP2001529418A JP2003512306A (ja) 1999-10-08 2000-09-29 カチオン性ｄｏｓｐｅｒビロソーム
SK478-2002A SK4782002A3 (en) 1999-10-08 2000-09-29 Lipidic vesicles, a method for the manufacture thereof pharmaceutical composition containing the same and use thereof
TR2002/00930T TR200200930T2 (tr) 1999-10-08 2000-09-29 Katyonik dosper virosomlar
AT00967824T ATE258428T1 (de) 1999-10-08 2000-09-29 Kationische dosper virosomen
RU2002112224/15A RU2002112224A (ru) 1999-10-08 2000-09-29 Катионные виросомы DOSPER
ES00967824T ES2215073T3 (es) 1999-10-08 2000-09-29 Virosomas de dosper cationicos.
CO00076243A CO5280052A1 (es) 1999-10-08 2000-10-06 Virosomas cationicos dosper
PE2000001071A PE20010703A1 (es) 1999-10-08 2000-10-06 Virosomas cationicos dosper
NO20021607A NO20021607L (no) 1999-10-08 2002-04-05 Kationiske DOSPER-virosomer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08
EP96107282 1996-05-08

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP1997/002268 Continuation-In-Part WO1997041834A1 (en) 1996-05-08 1997-05-04 Cationic virosomes as transfer system for genetic material
US09171882 Continuation-In-Part 1998-12-30

Publications (1)

Publication Number Publication Date
US6210708B1 true US6210708B1 (en) 2001-04-03

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/414,872 Expired - Fee Related US6210708B1 (en) 1996-05-08 1999-10-08 Cationic virosomes as transfer system for genetic material

Country Status (28)

Country Link
US (1) US6210708B1 (enrdf_load_stackoverflow)
EP (1) EP0902682A2 (enrdf_load_stackoverflow)
JP (1) JP2000509404A (enrdf_load_stackoverflow)
KR (1) KR100536983B1 (enrdf_load_stackoverflow)
CN (1) CN1271992C (enrdf_load_stackoverflow)
AR (1) AR007054A1 (enrdf_load_stackoverflow)
AU (1) AU710170B2 (enrdf_load_stackoverflow)
BG (1) BG102880A (enrdf_load_stackoverflow)
BR (1) BR9709224A (enrdf_load_stackoverflow)
CA (1) CA2253561A1 (enrdf_load_stackoverflow)
CO (1) CO4600638A1 (enrdf_load_stackoverflow)
CZ (1) CZ299809B6 (enrdf_load_stackoverflow)
EA (1) EA003130B1 (enrdf_load_stackoverflow)
GT (1) GT199700058A (enrdf_load_stackoverflow)
HR (1) HRP970234B1 (enrdf_load_stackoverflow)
HU (1) HUP9901790A3 (enrdf_load_stackoverflow)
ID (1) ID17934A (enrdf_load_stackoverflow)
NO (1) NO327726B1 (enrdf_load_stackoverflow)
NZ (1) NZ332666A (enrdf_load_stackoverflow)
OA (1) OA10916A (enrdf_load_stackoverflow)
PA (1) PA8429201A1 (enrdf_load_stackoverflow)
PE (1) PE65198A1 (enrdf_load_stackoverflow)
PL (1) PL199201B1 (enrdf_load_stackoverflow)
SK (1) SK152698A3 (enrdf_load_stackoverflow)
SV (1) SV1997000032A (enrdf_load_stackoverflow)
TN (1) TNSN97080A1 (enrdf_load_stackoverflow)
WO (1) WO1997041834A1 (enrdf_load_stackoverflow)
ZA (1) ZA973885B (enrdf_load_stackoverflow)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021768A1 (en) * 2001-07-23 2003-01-30 Yuqiao Shen Viral mutants that selectively replicate in targeted human cancer cells
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US20030139361A1 (en) * 2000-01-21 2003-07-24 Kazuhiro Yuda Drug for gene therapy
US20030226466A1 (en) * 1999-12-17 2003-12-11 Guenter Duerschinger Ignition capsule, which can be inductively activated, for occupant restraint systems, and a test circuit for said ignition capsule
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
WO2004045582A1 (en) * 2002-11-21 2004-06-03 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20110052539A1 (en) * 2006-09-15 2011-03-03 David Stojdl Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
US8470972B2 (en) 2003-10-24 2013-06-25 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8541550B2 (en) 2003-10-24 2013-09-24 Gencia Corporation Methods and compositions for delivering polynucleotides
US8927691B2 (en) 2003-10-24 2015-01-06 Gencia Corporation Transducible polypeptides for modifying metabolism
US8952133B2 (en) 2003-10-24 2015-02-10 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissue
US20210206812A1 (en) * 2011-10-07 2021-07-08 Isd Immunotech Aps Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9224398A (en) * 1997-09-08 1999-03-29 Promega Corporation Method of (in vivo) transformation utilizing lipid vehicles
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
WO2001026628A1 (en) * 1999-10-08 2001-04-19 Nika Health Products Limited Cationic dosper virosomes
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
CN109789214B (zh) 2016-09-27 2022-06-28 卡姆拉斯公司 包含edta烷基铵盐的混合物和制剂
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
WO1991016024A1 (en) 1990-04-19 1991-10-31 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0497997A1 (en) 1991-02-02 1992-08-12 Nika Health Products Limited Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
WO1992019267A1 (en) 1991-05-08 1992-11-12 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
WO1993014744A1 (en) 1992-02-04 1993-08-05 Chiron Corporation Non-toxic lipid vaccine formulations
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
WO1995030330A1 (en) 1994-05-10 1995-11-16 Dzau Victor J Method for in vivo delivery of therapeutic agents via liposomes
WO1995032706A1 (en) 1994-05-31 1995-12-07 Inex Pharmaceuticals Corp. Virosome-mediated intracellular delivery of therapeutic agents
WO1996014831A1 (fr) 1994-11-14 1996-05-23 Pasteur Merieux Serums & Vaccins Adjuvant pour composition vaccinale

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
WO1991016024A1 (en) 1990-04-19 1991-10-31 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0497997A1 (en) 1991-02-02 1992-08-12 Nika Health Products Limited Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
WO1992013525A1 (en) * 1991-02-02 1992-08-20 Nika Health Products Limited Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
WO1992019267A1 (en) 1991-05-08 1992-11-12 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
WO1993014744A1 (en) 1992-02-04 1993-08-05 Chiron Corporation Non-toxic lipid vaccine formulations
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
WO1995030330A1 (en) 1994-05-10 1995-11-16 Dzau Victor J Method for in vivo delivery of therapeutic agents via liposomes
WO1995032706A1 (en) 1994-05-31 1995-12-07 Inex Pharmaceuticals Corp. Virosome-mediated intracellular delivery of therapeutic agents
WO1996014831A1 (fr) 1994-11-14 1996-05-23 Pasteur Merieux Serums & Vaccins Adjuvant pour composition vaccinale

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Anderson, Nature 392: 25-30, Human gene therapy, Apr. 1998. *
Behr, Jean-Paul, et al. "Efficient Gene Transfer into Mammalian Primary Endocrine Cells with Lipopolyamine-Coated DNA", Proc. Natl. Acad. Sci. USA, vol. 86, Sep. 1989, pp. 6982-6986.
Calabretta, Bruno, et al. "Normal and Leukemic Hematopoietic Cells Manifest Differential Sensitivity to Inhibitory Effects of c-myb Antisense Oligodeoxynucleotides: An In Vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA, vol. 88, Mar. 1991, pp. 2351-2355.
Chen, Phang-Lang, et al. "Genetic Mechanisms of Tumor Suppression by the Human p53 Gene", Science, vol. 250, Dec. 14, 1990, pp. 1576-1580.
Felgner, Philip L., et al. "Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure", Proc. Natl Acad. Sci. USA, vol. 84, Nov. 1987, pp. 7413-7417.
Hoekstra, Dick, et al. "Fluorescence Method for Measuring the Kinetics of Fusion Between Biological Membranes", Biochemistry, 1984, 23, pp. 5675-5681.
Luscher-Mattli, M., et al. "A Comparative Study of the Effect of Dextran Sulfate on the Fusion and the In Vitro Replication of Influenza A and B, Semliki Forest, Vesicular Stomatitis, Rabies, Sendai, and Mumps Virus", Archives of Virology, 130, 1993, pp. 317-326.
Martin, Francis J., et al. "Irreversable Coupling of Immunoglobulin Fragments to Preformed Vesicles: An Improved Method for Liposome Targeting", The Journal of Biological Chemistry, vol. 257, No. 1, Jan. 10, 1982, pp. 286-288.
Moolten, Frederick L. "Tumor Chemosensitivity Conferred by Inserted Herpes Thymidine Kinase Genes: Paradigm for a Prospective Cancer Control Strategy", Cancer Research, 46, Oct. 1986, pp. 5276-5281.
Morishita, Ryuichi, et al. "Enhanced Effectiveness of Antisense Oligonucleotides in Vascular Smooth Muscle Cells (VSMC) by HVJ Mediated Gene Transfer", J. Cell. Biochem., 1993, 17E, pp. 239.
Plautz, Gregory E., et al. "Immunotherapy of Maliganacy by In Vivo Gene Transfer into Tumors", Proc. Natl. Acad. Sci. USA, vol. 90, May 1993, pp. 4645-4649.
Ruysschaert, Jean-Marie, et al. "A Novel Cationic Amphiphile for Transfection of Mammalian Cells", Biochemical and Biophysical Research Communications, vol. 203, No. 3, 1994, pp. 1622-1628.
Sizer, Philip J. H., et al. "Functional Reconstitution of the Integral Membrane Proteins of Influenza Virus into Phospholipid Liposomes", Biochemistry 1987, 26, pp. 5106-5113.
Skehel, John J., et al "The Polypeptide Composition of Influenza A Viruses", Virology, 44, 1971, pp. 396-408.
Stegmann et al., Biochemistry 24: 3107-3113, Kinetics of pH-dependent fusion between influenza virus and liposomes, 1985.*
Stegmann, Toon, et al. "Functional Reconsitution of Influenza Virus Envelopes", The EMBO Journal, vol. 6, No. 9, 1987, pp. 2651-2659.
Szczylik, Cezary, et al. "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides", Science, vol. 253, Aug. 2, 1991, pp. 562-565.
Tepper, Robert, I., et al. "Murine Interleuken-4 Displays Potent Anti-Tumor Activity in Vivo", Cell, vol. 57, May 5, 1989, pp. 503-512.
Townsend, Sarah E., et al. "Tumor Rejection after Direct Costimulation of CD8+T Cells by B7-Transfected Melanoma Cells", Science, vol. 259, Jan. 15, 1993, pp. 368-370.
Vainstein, A., et al. "Fusogenic Reconstituted Sendai Virus Envelopes as a Vehicle for Instroducing DNA into Viable Mammalian Cells", Methods in Enzymology, vol. 101, 1983, pp. 492-513.
Verma et al., Nature 389: 239-242, Gene therapy-promises, problems, and prospects, Sep. 1997.*
Yang, Yiping, et al. "Cellular Immunity to Viral Antigens Limits El-Deleted Adenoviruses for Gene Therapy", Proc. Natl Acad. Sci. USA, vol. 91, May 1994, pp. 4407-4411.

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US20030226466A1 (en) * 1999-12-17 2003-12-11 Guenter Duerschinger Ignition capsule, which can be inductively activated, for occupant restraint systems, and a test circuit for said ignition capsule
US20030139361A1 (en) * 2000-01-21 2003-07-24 Kazuhiro Yuda Drug for gene therapy
US20030021768A1 (en) * 2001-07-23 2003-01-30 Yuqiao Shen Viral mutants that selectively replicate in targeted human cancer cells
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
AU2003288119B2 (en) * 2002-11-21 2009-08-20 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
US20090280163A1 (en) * 2002-11-21 2009-11-12 Pevion Biotech Ltd. High-Efficiency Fusogenic Vesicles, Methods of Producing Them, and Pharmaceutical Compositions Containing Them
EA008497B1 (ru) * 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
US20050064024A1 (en) * 2002-11-21 2005-03-24 Sonia Vadrucci High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
US7329807B2 (en) * 2002-11-21 2008-02-12 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
WO2004045582A1 (en) * 2002-11-21 2004-06-03 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
US8541550B2 (en) 2003-10-24 2013-09-24 Gencia Corporation Methods and compositions for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8470972B2 (en) 2003-10-24 2013-06-25 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8927691B2 (en) 2003-10-24 2015-01-06 Gencia Corporation Transducible polypeptides for modifying metabolism
US8952133B2 (en) 2003-10-24 2015-02-10 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissue
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
US20110052539A1 (en) * 2006-09-15 2011-03-03 David Stojdl Oncolytic rhabdovirus
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US9572883B2 (en) 2006-09-15 2017-02-21 Turnstone Limited Partnership Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
US20210206812A1 (en) * 2011-10-07 2021-07-08 Isd Immunotech Aps Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses

Also Published As

Publication number Publication date
CN1225007A (zh) 1999-08-04
NO985137L (no) 1999-01-04
SK152698A3 (en) 1999-05-07
CZ361498A3 (cs) 1999-03-17
PL329853A1 (en) 1999-04-12
PL199201B1 (pl) 2008-08-29
NO327726B1 (no) 2009-09-14
KR20000010780A (ko) 2000-02-25
ZA973885B (en) 1998-11-06
AR007054A1 (es) 1999-10-13
EP0902682A2 (en) 1999-03-24
BR9709224A (pt) 1999-08-10
CN1271992C (zh) 2006-08-30
KR100536983B1 (ko) 2006-06-29
TNSN97080A1 (fr) 2005-03-15
OA10916A (en) 2003-02-21
EA199800992A1 (ru) 1999-06-24
AU2776697A (en) 1997-11-26
ID17934A (id) 1998-02-12
EA003130B1 (ru) 2003-02-27
BG102880A (en) 1999-05-31
PA8429201A1 (es) 2000-05-24
HRP970234A2 (en) 1998-06-30
CA2253561A1 (en) 1997-11-13
JP2000509404A (ja) 2000-07-25
NO985137D0 (no) 1998-11-04
NZ332666A (en) 2000-05-26
HRP970234B1 (en) 2002-04-30
WO1997041834A1 (en) 1997-11-13
SV1997000032A (es) 1998-03-27
AU710170B2 (en) 1999-09-16
HUP9901790A3 (en) 2010-11-29
CZ299809B6 (cs) 2008-12-03
PE65198A1 (es) 1998-10-16
GT199700058A (es) 1998-10-29
CO4600638A1 (es) 1998-05-08
HUP9901790A2 (hu) 1999-08-30

Similar Documents

Publication Publication Date Title
US6210708B1 (en) Cationic virosomes as transfer system for genetic material
US8771728B2 (en) Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) Stable lipid-comprising drug delivery complexes and methods for their production
AU778399B2 (en) Cationic DOSPER virosomes
WO2025008006A1 (zh) 脂质化合物和脂质纳米颗粒组合物
HK1021317A (en) Cationic virosomes as transfer system for genetic material
Gould-Fogerite et al. Liposomes: use as gene transfer vehicles and vaccines.
JPH11187873A (ja) 細胞内物質導入ベクター
Sandhu Optimization of the intracellular delivery properties of non-viral DNA carrier systems

Legal Events

Date Code Title Description
AS Assignment

Owner name: NIKA HEALTH PRODUCTS LIMITED, LIECHTENSTEIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WALTI, ERNST RUDOLF;GLUCK, REINHARD;KLEIN, PETER;REEL/FRAME:010311/0564

Effective date: 19990916

CC Certificate of correction
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20130403